Cancer Epidemiology Biomarkers & Prevention, Vol 6, Issue 10 849-855, Copyright © 1997 by American Association for Cancer Research

ARTICLES

DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia

IV Boiko, MF Mitchell, DK Pandey, RA White, W Hu, A Malpica, K Nishioka, CW Boone, EN Atkinson and WN Hittelman
Department of Clinical Investigation, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

Cervical intraepithelial neoplasia grade 3 (CIN 3) is considered a high-risk precursor of invasive cervical cancer. alpha-Difluoromethylornithine (DFMO) is a promising antiproliferative chemopreventive agent. The purpose of this study was to evaluate image cytometric measurement of nuclear DNA (ICM-DNA) as a surrogate end point biomarker (SEB) in a Phase I trial of DFMO for CIN. Thirty patients with CIN 3 were treated with DFMO at five doses, ranging from 0.0625 to 1.0 g/m2/day, for 1 month. Half of the patients had histological responses. Twenty-five pre- and posttreatment cervical biopsy specimens (from 11 responders and 14 nonresponders) were available for this analysis. ICM-DNA was performed on 4-micron sections cut from formalin-fixed tissue blocks and stained with a thionin-SO2 Feulgen reaction. ICM-DNAs for each case were expressed as normalized measurements (against the nuclear modal absorbance of lymphocytes) of the absorbance of each cell of interest and were presented in bar histograms. The mean normalized summed absorbance (sigma ODn) was obtained as a mean histogram of the cell population of interest. Nineteen (76%) of 25 patients had a significant decrease in sigma ODn after DFMO treatment. Posttreatment values were significantly lower than pretreatment values in a paired analysis, and responders had significantly lower values than nonresponders. Analyses of different ICM-DNA references, including percentile values of sigma ODn distribution, DNA malignancy grade, and 5c exceeding rate, showed a decrease of mean sigma ODn during DFMO treatment. In addition, the summed posttreatment sigma ODn histograms also showed progressively shorter right shoulders compared with pretreatment histograms in both responders and nonresponders. We concluded that the modulation of sigma ODn reflected the chemoprevention effect of DFMO even before morphological changes appeared, and thus, ICM-DNA may be useful as a SEB in chemoprevention trials of DFMO. Additional reasons for using ICM-DNA as a SEB are the relative simplicity of its use, the high accuracy of the results, the low cost of the reagents, the ability to use small tissue samples, and the objectivity and reproducibility of the procedure.

This article has been cited by other articles:

				A.-T. Vlastos, L. A. West, E. N. Atkinson, I. Boiko, A. Malpica, W. K. Hong, and M. Follen Results of a Phase II Double-Blinded Randomized Clinical Trial of Difluoromethylornithine for Cervical Intraepithelial Neoplasia Grades 2 to 3 Clin. Cancer Res., January 1, 2005; 11(1): 390 - 396. [Abstract] [Full Text] [PDF]

				C. J. Fabian, B. F. Kimler, D. A. Brady, M. S. Mayo, C. H. J. Chang, J. A. Ferraro, C. M. Zalles, A. L. Stanton, S. Masood, W. E. Grizzle, et al. A Phase II Breast Cancer Chemoprevention Trial of Oral {alpha}-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers Clin. Cancer Res., October 1, 2002; 8(10): 3105 - 3117. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, C. C. Sigman, K. M. Johnson, C. W. Boone, P. Greenwald, J. A. Crowell, E. T. Hawk, and L. A. Doody Perspectives on Surrogate End Points in the Development of Drugs that Reduce the Risk of Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2000; 9(2): 127 - 137. [Abstract] [Full Text]

				J. A. O'Shaughnessy, L. M. Demers, S. E. Jones, J. Arseneau, P. Khandelwal, T. George, R. Gersh, D. Mauger, and A. Manni {{alpha}}-Difluoromethylornithine as Treatment for Metastatic Breast Cancer Patients Clin. Cancer Res., November 1, 1999; 5(11): 3438 - 3444. [Abstract] [Full Text] [PDF]